# Testing the Safety and Feasibility of Immunotherapy Drugs, Botensilimab and Balstilimab, Before Surgery for Clear Cell Renal Cell Carcinoma, NEO RoBOT Trial

> **NCT07516366** · PHASE2 · NOT_YET_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 16 (estimated)

## Conditions studied

- Clear Cell Renal Cell Carcinoma
- Stage II Renal Cell Cancer AJCC v8
- Stage III Renal Cell Cancer AJCC v8
- Stage IV Renal Cell Cancer AJCC v8

## Interventions

- **BIOLOGICAL:** Balstilimab
- **PROCEDURE:** Biospecimen Collection
- **BIOLOGICAL:** Botensilimab
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Nephrectomy
- **OTHER:** Questionnaire Administration

## Key facts

- **NCT ID:** NCT07516366
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-21
- **Primary completion:** 2027-08-30
- **Final completion:** 2027-08-30
- **Target enrollment:** 16 (ESTIMATED)
- **Last updated:** 2026-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07516366

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07516366, "Testing the Safety and Feasibility of Immunotherapy Drugs, Botensilimab and Balstilimab, Before Surgery for Clear Cell Renal Cell Carcinoma, NEO RoBOT Trial". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07516366. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*